Pawel Baranczewski

Head of Unit: ADME of Therapeutics, Uppsala University

Keywords
Key publications

Wegler CH, Saleh A, Lindqvist A, Nordeng A, Smeraglia J, Baranczewski P (2022)
Simple and rapid quantification of cetirizine, venlafaxine, and O-desmethylvenlafaxine in human breast milk, and metformin in human milk and plasma with UHPLC-MS/MS.
Journal of Chromatography B, 2022, 1205, 1-9.

Brem J, Panduwawala T, Hansen JU, Hewitt J, Liepins E, …, Baranczewski P, Cantón R, McElroy SP, Jones PS, Baquero F, Suna E, Morrison A, Walsh TR, Schofield CJ. (2021)
Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors.
Nature Chemistry, 2022, 14(1), 15-24.

Olliver M, Griestop L, Hughes D, Belfrage AK, Gising J, Baranczewski P, Vingsbo Lundberg C, Karlén A (2021)
ENABLE: an engine for European antibacterial drug discovery and development.
Nat Rev Drug Discov, 20(6), 407-408.

Visnes T, Cázares-Körner A, Hao W, Wallner O, Masuyer G, Loseva O, Mortusewicz O, Wiita E, Sarno A, Manoilov A, Astorga-Wells J, Jemth AS, Pan L, Sanjiv K, Karsten A, Gokturk C, Grube M, Homan EJ, Hanna BMF, Paulin CBJ, Pham T, Rasti A, von Nicolai C, Benitez-Buelga C, Koolmeister T, Ivanic D, Iliev P, Scobie M, Krokan HE, Baranczewski P, Artursson P, Altun M, Jenmalm Jensen A, Kalderén Ch, Ba X, Zubarev RA, Stenmark P, Boldogh I, Warpman Berglund U, Helleday T (2018)
Small molecule inhibitor of OGG1 suppresses pro-inflammatory gene expression and inflammation.
Science, 362 (6416), 834-839.

Sohlenius-Sternbeck AK, Janson J, Bylund J, Baranczewski P, Breitholtz-Emanuelsson A, Hu Y, Tsoi C, Lindgren A, Gissberg O, Bueters T, Briem S, Juric S, Johansson J, Bergh M, Hoogstraate J. (2016)
Optimizing DMPK Properties: Experiences from a Big Pharma DMPK Department.
Curr Drug Metab, 17, 253-270.

Gad H., Koolmeister T., Jemth A.-S., Eshtad S., Jacques S.A., Ström C.E., Svensson L.M., Schultz N., Lundbäck T., Einarsdottir B.O., Saleh A., Göktürk C., Baranczewski P., … & Thomas Helleday (2014)
MTH1 inhibition kills eradicates cancer cells by preventing sanitation of the dNTP pool.
Nature, 508, 215–221.

Pawel Baranczewski

Associate Professor (Docent) in preclinical drug development. 14 years of industrial experience within the area of drug discovery and development. Particular expertise in ADME, pharmacokinetics (PK) and pharmaceutical profiling of drug compounds. Demonstrated ability to set up and run highly functioning laboratories. Hands-on experience with in vitro ADME, in vivo PK and pharmaceutical profiling assays, PBPK simulations and PKPD modelling as well as with LC-MS/MS technique. More than a decade of experience within leadership and coordination of interdisciplinary teams.

Group Members

Anders Eneroth
Annika Lindqvist
Aljona Saleh
Ivailo Simoff
Richard Svensson
Jimmy Ytterberg

Last updated: 2024-03-07

Content Responsible: David Gotthold(david.gotthold@scilifelab.se)